RLY-2139

N/A

Report date: 2023/10/09 17:11:58
NME

Base Information

Drug NameRLY-2139
Drug Alias NameRLY-2139
ClassificationSmall molecules
Mechanisms of ActionCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRelay Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRelay Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A